PURPOSE: To describe the outcome of childhood primary central nervous system lymphoma (PCNSL) treated with chemotherapy alone or with chemotherapy plus cranial radiotherapy (CRT). METHODS: Retrospective chart review of children with PCNSL at six tertiary care pediatric centers. RESULTS: Eight immunocompetent and four immunocompromised children were included. Ten children received chemotherapy alone without CRT, with most receiving high-dose methotrexate and high-dose cytarabine. Five year event-free survival (EFS) in this group was 70.0 +/- 14.5%. Two children received chemotherapy plus CRT; one relapsed and died while the other is alive in remission. Three children died, including two from relapsed disease. The other child with human immunodeficiency virus infection died of an opportunistic infection while in remission following chemotherapy alone. CONCLUSIONS: Most children with PCNSL can achieve long-term remissions with chemotherapy alone without CRT. Multi-center prospective studies are needed to confirm or refute these results in a larger number of patients.
PURPOSE: To describe the outcome of childhood primary central nervous system lymphoma (PCNSL) treated with chemotherapy alone or with chemotherapy plus cranial radiotherapy (CRT). METHODS: Retrospective chart review of children with PCNSL at six tertiary care pediatric centers. RESULTS: Eight immunocompetent and four immunocompromised children were included. Ten children received chemotherapy alone without CRT, with most receiving high-dose methotrexate and high-dose cytarabine. Five year event-free survival (EFS) in this group was 70.0 +/- 14.5%. Two children received chemotherapy plus CRT; one relapsed and died while the other is alive in remission. Three children died, including two from relapsed disease. The other child with human immunodeficiency virus infection died of an opportunistic infection while in remission following chemotherapy alone. CONCLUSIONS: Most children with PCNSL can achieve long-term remissions with chemotherapy alone without CRT. Multi-center prospective studies are needed to confirm or refute these results in a larger number of patients.
Authors: Oussama Abla; Sheila Weitzman; Jean-Yves Blay; Brian Patrick O'Neill; Lauren E Abrey; Edward Neuwelt; Nancy D Doolittle; Joachim Baehring; Kamnesh Pradhan; S Eric Martin; Michael Guerrera; Shafqat Shah; Hervé Ghesquieres; Michael Silver; Rebecca A Betensky; Tracy Batchelor Journal: Clin Cancer Res Date: 2011-01-11 Impact factor: 12.531
Authors: Jong Hyung Yoon; Hyoung Jin Kang; Hyery Kim; Ji Won Lee; June Dong Park; Kyung Duk Park; Hee Young Shin; Hyo Seop Ahn Journal: J Korean Med Sci Date: 2012-10-30 Impact factor: 2.153
Authors: Heike Thorer; Martin Zimmermann; Olga Makarova; Ilske Oschlies; Wolfram Klapper; Peter Lang; Arend von Stackelberg; Gudrun Fleischhack; Jennifer Worch; Heribert Juergens; Wilhelm Woessmann; Alfred Reiter; Birgit Burkhardt Journal: Haematologica Date: 2014-08-08 Impact factor: 9.941
Authors: Marcus D Mazur; Vijay M Ravindra; Mouied Alashari; Elizabeth Raetz; Matthew M Poppe; Robert J Bollo Journal: Childs Nerv Syst Date: 2015-02-15 Impact factor: 1.475
Authors: Andishe Attarbaschi; Oussama Abla; Leila Ronceray; Shweta Bansil; Simon Bomken; Birgit Burkhardt; Francecso Ceppi; Alan K S Chiang; Hema Dave; Alina Fedorova; Michael Henry; Janez Jazbec; Edita Kabickova; Rishi S Kotecha; Jelena Lazic; Jan Loeffen; Natalia Miakova; Tomoo Osumi; Marta Pillon; Apostolos Pourtsidis; Charlotte Rigaud; Gevorg Tamamyan; Sneha Tandon; Anne Uyttebroeck; Jamie Verdu-Amoros; Wilhelm Woessmann; Grazyna Wrobel; Lisa Giulino-Roth Journal: Blood Adv Date: 2019-12-23
Authors: Haneen Shalabi; Anne Angiolillo; Gilbert Vezina; James L Rubenstein; Stefania Pittaluga; Mark Raffeld; Leigh Marcus Journal: Pediatr Hematol Oncol Date: 2015-09-18 Impact factor: 1.969